Q: Hello Peter,
I would like your assessment of DXCM after the earnings call. The growth rate has not tapered, the valuation on P/E and P/B looks to be in line with growth companies such as CRWD, VEEV etc. The product has now access to the european market, which probably was not part of the equation earlier quarter. Apart from the impending retirement of a senior executive, what would cause the sharp drop relative to the market?
Would this be a candidate for capital loss sale and buy in Dec or Jan?
Look forward to your thoughts.
Regards
Rajiv
I would like your assessment of DXCM after the earnings call. The growth rate has not tapered, the valuation on P/E and P/B looks to be in line with growth companies such as CRWD, VEEV etc. The product has now access to the european market, which probably was not part of the equation earlier quarter. Apart from the impending retirement of a senior executive, what would cause the sharp drop relative to the market?
Would this be a candidate for capital loss sale and buy in Dec or Jan?
Look forward to your thoughts.
Regards
Rajiv